Leave Your Message
ADT1756-Human Anti-CD3xCD20 Bispecific Antibody
Hot

ADT1756-Human Anti-CD3xCD20 Bispecific Antibody

  • Catalog Number ADT1756
  • Host CHO Cells
  • Species Human
  • Target CD3xCD20
  • Application FuncS

CD3, T cell receptor complex (including CD3 γ/δ/ε/Zeta chains), is a core signaling molecule for T cell activation. CD20, a B cell surface antigen encoded by the MS4A1 gene, is the main target of monoclonal antibody therapies such as rituximab.

 

Alpha Lifetech provides pre-sales and after-sales services for our products, and our bispecific antibody solutions will provide technical support for your research.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.

Product Specification

Catalog Number

ADT1756

Product Name

ADT1756-Human Anti-CD3xCD20 Bispecific Antibody

Isotype

Human IgG1-kappa/lambdawith domain crossover, trivalent

Clonity

Monoclonal

Alternate Names

Human Anti-CD3 mAb, Anti-CD3 Monoclonal Antibody, CD3 recombinant antibody, Anti-CD3 Bispecific Antibody, Human Anti-CD20 mAb, CD20 recombinant antibody, Anti-CD20 Monoclonal Antibody, Anti-CD20 Bispecific Antibody

Official Symbol

CD3xCD20

Target 1

CD3

Gene ID 1

916

Target 2

CD20

Gene 2

931

Species

Human

Drug Name

Glofitamab

CAS Number

2229047-91-8

Product Description

Glofitamab is a bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Mechanism of Action

Glofitamab is a bispecific monoclonal antibody targeted towards CD20 surface antigens - found on B-cells - and CD3 protein complexes found on the surface of T-cells.It binds bivalently to CD20 and monovalently to CD3, thereby creating an immunological synapse that serves to recruit T-cells to CD20-expressing B-cells. This simultaneous binding allows for potent T-cell activation and proliferation which ultimately results in the lysis of the target B-cells.

Metabolism

The metabolism of glofitamab has not been directly studied. As with other therapeutic antibodies, it is likely metabolized primarily via catabolism to smaller peptides and amino acids.

Molecular Weight

194 KDa

Endotoxin

<1EU/mg. Determined by the LAL method.

Sterility

0.2 μM filtered.

Expression Host

CHO Cells

Size

1mg,5mg,50mg,100mg

Research Area

Cancer

Application

FuncS

Purity

>90%

Concentration

Batch dependent

Buffer

Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives

Recommended Dilution Buffer

ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives.

Storage

2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage.

Shipping Condition

Shipped on ice packs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. 

Note

For Research Use Only!

Reference

1. Wang C, Liu Y: Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting. J Hematol Oncol. 2023 Mar 10;16(1):20. doi: 10.1186/s13045-023-01420-w.
2. Gonzalez Barca E: Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. Front Immunol. 2022 Jul 19;13:909008. doi: 10.3389/fimmu.2022.909008. eCollection 2022.

 

FAQ

Leave Your Message